Key data
Open—
From 52W high—
Volume—
Market cap—
P/E (TTM)—
P/S (TTM)—
Div yield—
Key data
Open
—
From 52W high
—
Volume
—
Market cap
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Cellectis S.A. (NASDAQ:CLLS) is a French clinical-stage biotechnology company founded in 1999 and headquartered in Paris. The company specializes in developing gene-edited immunotherapy treatments for cancer, particularly focusing on allogeneic CAR-T cell therapies that can be manufactured at scale and used across multiple patients. Cellectis has evolved from its early gene-editing platform origins to become a leading developer of "off-the-shelf" cancer immunotherapies, with multiple clinical programs in various stages of development and a significant strategic partnership with pharmaceutical giant AstraZeneca established in 2024.
Latest newsMore news →
Cellectis S.A. announced the presentation of preclinical data on .HEAL-101, its in vivo base-editing candidate targeting APOC3 for severe hypertriglyceridemia, at the ESGCT 2026 congress.8d agoSBS Law announced a fraud investigation into Cellectis S.A. and invited CLLS investors to join it.46d agoHolzer & Holzer, LLC announced an investigation into whether Cellectis S.A. complied with federal securities laws after Cellectis said it would exit development of lasme-cel and eti-cel.48d ago